Simultaneously, ARK has been bolstering its stake in Absci Corp (NASDAQ:ABSI), with the ARKG ETF purchasing 20,310 shares worth $81,849. This buy is part of a recent trend, as ARK previously acquired ...

Simultaneously, ARK has been bolstering its stake in Absci Corp (NASDAQ:ABSI), with the ARKG ETF purchasing 20,310 shares worth $81,849. This buy is part of a recent trend, as ARK previously acquired ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street's Radar. In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other ...

Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that ...

Fintel reports that on January 22, 2025, Needham initiated coverage of Absci (NasdaqGS:ABSI) with a Buy recommendation. Analyst Price Forecast Suggests 164.38% Upside As of December 23 ...

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech ...

This approach allows Absci to quickly advance and monetize clinical-stage assets, aligning well with its AI/ML-driven platform. Price Action: ABSI stock is up 23% at $3.96 at the last check on ...

Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...

Wednesday, Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00. The ...